MedTrace Logo

Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting

NCT05615129 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2022-11-29

No results posted yet for this study

Summary

It is reported that compared to chemotherapy alone, immunochemotherapy has significantly improved the overall survival of patients with advanced metastatic ESCC. However, there are still more than 30% of patients who cannot benefit from this treatment modality. In addition to these factors, the time-of-day infusion and administration sequence of immunochemotherapy have been reported to be associated with tumor responses and overall survival. In this study, The investigators aimed to explore the roles of infusion time and administration sequence of immunochemotherapy in predicting tumor responses and overall survival in patients with advanced ESCC.

Conditions

  • Esophagus Cancer

Sponsors & Collaborators

  • First Affiliated Hospital of Shantou University Medical College

    collaborator OTHER

  • Peking University Shenzhen Hospital

    collaborator OTHER

  • Guangdong Provincial People's Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-08-30
Completion
2022-10-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05615129 on ClinicalTrials.gov